Viveka Roychowdhury

As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this government’s achievements…

Since 2013, Novartis has sharpened focus, with last April's asset swaps with GSK and Eli Lilly the next step in this process. In…

As we settle into FY2016, it is worth taking a quick look at some of the earning previews of the last quarter

Success hinges on the company getting its GMP right and surviving the glare of regulatory scrutiny

Finance Minister Arun Jaitley’s first Union Budget had nothing special for the pharmaceutical industry

Other topics at the ASSOCHAM Pharma Summit included changes in drug pricing, the impending revision of NLEM-2011, and amendments…

As in previous years, we mark this Women's Day with a cover story section devoted to women's health issue

The draft National IPR policy, unveiled last December by the Department of Industrial Policy & Promotion (DIPP), has already…

In a free-wheeling conversation with Viveka Roychowdhury, Patrick Figgis, Global Health Leader, PwC and Sujay Shetty,…

After three consecutive years of negative EBITDA, Panacea Biotec looks set to script a successful revival. Dr Rajesh Jain, Joint…